Cargando…

Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients

Background: The suppression of tumorigenicity 2 (ST2) is associated with cardiac remodeling and tissue fibrosis. It is well known as a novel biomarker on predictor of cardiovascular events in patients with heart failure. In patients needed to start dialysis treatment, most of them had congestive hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Suk Min, Kim, Sun Hwa, Kim, Yaeni, Yoon, Hye Eun, Shin, Seok Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001418/ https://www.ncbi.nlm.nih.gov/pubmed/29910678 http://dx.doi.org/10.7150/ijms.23638

Ejemplares similares

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes
por: Moon, Jong Joo, et al.
Publicado: (2023)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study
por: Rezar, Richard, et al.
Publicado: (2021)

The Clinical Usefulness of Measurement of Visceral Fat Area Using Multi-Frequency Bioimpedance: The Association with Cardiac and Renal Function In General Population with Relatively Normal Renal Function
por: Yoon, Hye Eun, et al.
Publicado: (2017)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

A Pilot Trial to Examine the Changes in Carotid Arterial Inflammation in Renal Transplant Recipients as Assessed by (18)F-Fluorodeoxyglucose ((18)F-FDG) Positron Emission Tomography Computed Tomography (PET/CT)
por: Yoon, Hye Eun, et al.
Publicado: (2018)

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
por: Gül, İbrahim, et al.
Publicado: (2017)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Prognostic Role of High-sensitivity Cardiac Troponin I and Soluble Suppression of Tumorigenicity-2 in Surgical Intensive Care Unit Patients Undergoing Non-cardiac Surgery
por: Yang, Hyun Suk, et al.
Publicado: (2018)

A pilot trial to evaluate the clinical usefulness of contrast-enhanced ultrasound in predicting renal outcomes in patients with acute kidney injury
por: Yoon, Hye Eun, et al.
Publicado: (2020)

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review
por: Ahmadzadeh, Koohyar, et al.
Publicado: (2023)

Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts
por: Hwang, Hyeon Seok, et al.
Publicado: (2018)

Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study
por: Wang, Zhiyu, et al.
Publicado: (2020)

Plasma Brain-derived Neurotrophic Factor in Hemodialysis Patients
por: Shin, Seok Joon, et al.
Publicado: (2012)

Correlation between Statin Solubility and Mortality in Patients on Chronic Hemodialysis
por: Kang, Seok-Hui, et al.
Publicado: (2023)

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis
por: Guo, Guangying, et al.
Publicado: (2021)

Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction
por: Kim, Min, et al.
Publicado: (2021)

Hypermagnesemia Accompanied with Colonic Perforation in a Hemodialysis Patient
por: Yoon, Hye Eun, et al.
Publicado: (2013)

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure
por: Alladina, Jehan W., et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study
por: Hou, Wenquan, et al.
Publicado: (2023)

Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
por: Kim, Hanah, et al.
Publicado: (2017)

The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy
por: Iqbal, Mohammad, et al.
Publicado: (2023)

Downregulation of ADAMTS3 Suppresses Stemness and Tumorigenicity in Glioma Stem Cell
por: Kim, Hyun‐Jin, et al.
Publicado: (2022)

Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis
por: Zhang, Yan, et al.
Publicado: (2021)

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation
por: Tan, Ruopeng, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study
por: Hou, Wenquan, et al.
Publicado: (2023)

Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure
por: Sun, Yanxiang, et al.
Publicado: (2022)

Changes of Plasma Angiotensin-Converting Enzyme Activity during Hemodialysis(*)
por: Koo, Wan Suh, et al.
Publicado: (1987)

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
por: Luk, King Sum, et al.
Publicado: (2017)

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range
por: Hasan, Amal, et al.
Publicado: (2020)

KPT6566 induces apoptotic cell death and suppresses the tumorigenicity of testicular germ cell tumors
por: Sun, Ruijing, et al.
Publicado: (2023)

Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer
por: Lee, Jeong Eon, et al.
Publicado: (2005)

miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC
por: Choi, Jae Yeon, et al.
Publicado: (2021)

Corrigendum to: Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Inhibition of Hepatic Stellate Cell Activation Suppresses Tumorigenicity of Hepatocellular Carcinoma in Mice
por: Kang, Min-Jung, et al.
Publicado: (2021)

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
por: Gerber, Yariv, et al.
Publicado: (2017)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cjpm4b0a4llg97e97c9tsnifp7